A phase 2, randomized, dose-finding study of the novel once-weekly human glp-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
Participants were randomly assigned in a 1:1 ratio to receive either semaglutide 50 mg or a placebo once daily for 68 weeks
And as always, discuss with your healthcare provider or a dietitian about your diet while on GLP-1 therapy, especially if you have any symptoms of not eating enough
(Ask what nutrition support is available as part of your program.) Book a consultation: Maryland Trim Clinic, Laurel, MD 20708, (301) 960-4811
Our twice-weekly dosing protocol uses smaller doses, which many patients find easier to tolerate compared to standard weekly injections
However, robust clinical trial evidence is lacking, and current NICE guidance does not recommend GLP-1 agonists for treating alcohol use disorder